Amundi Buys 232,988 Shares of United Therapeutics Corporation $UTHR

Key Points

• Amundi significantly increased its stake in United Therapeutics Corporation by 198.8%, owning approximately 0.78% of the company worth $107.6 million after purchasing an additional 232,988 shares.
• Multiple analysts have revised their price targets for United Therapeutics, with Jefferies Financial Group raising its target from $432 to $564, indicating strong optimism about the company's future performance.
• Despite the positive outlook, United Therapeutics reported a miss on earnings with an EPS of $6.41, lower than the expected $6.80, and quarterly revenue also slightly below estimates.

Amundi boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 198.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 350,193 shares of the biotechnology company's stock after purchasing an additional 232,988 shares during the period. Amundi owned 0.78% of United Therapeutics worth $107,635,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. SVB Wealth LLC acquired a new stake in United Therapeutics during the first quarter valued at $32,000. Sound Income Strategies LLC acquired a new stake in United Therapeutics during the first quarter valued at $49,000. State of Wyoming acquired a new stake in United Therapeutics during the fourth quarter valued at $62,000. Brooklyn Investment Group boosted its position in United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. Finally, WPG Advisers LLC acquired a new stake in United Therapeutics during the first quarter valued at $60,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on UTHR. Jefferies Financial Group lifted their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a report on Thursday, August 14th. HC Wainwright raised their target price on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday. Wells Fargo & Company raised their target price on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a report on Wednesday, September 3rd. Finally, Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $429.62.

United Therapeutics Stock Performance

NASDAQ UTHR traded down $5.90 during trading on Monday, reaching $394.62. 623,780 shares of the company traded hands, compared to its average volume of 865,507. The stock's 50 day moving average price is $309.83 and its two-hundred day moving average price is $305.60. The company has a market cap of $17.80 billion, a price-to-earnings ratio of 15.40, a P/E/G ratio of 6.11 and a beta of 0.62. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.85 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 106,181 shares of company stock valued at $35,537,239 over the last quarter. 10.30% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.